CleanSpark (CLSK) Jumps 5.58% on Analyst's 'Buy' Reco
We recently published . CleanSpark, Inc. (NASDAQ:CLSK) is one of the Wednesday's top performers.
CleanSpark grew its share prices for a second day on Wednesday, jumping 5.58 percent to close at $10.6 apiece after maintaining a 'buy' recommendation on its stock, buoyed by a significant milestone in its Bitcoin production.
On Tuesday, CleanSpark, Inc. (NASDAQ:CLSK) announced that it achieved its mid-year target of 50 exahashes per second (EH/s) of operational hashrate, becoming one of the few mining companies to reach such a threshold.
According to CleanSpark, Inc. (NASDAQ:CLSK) President and CEO Zach Bradford, the achievement 'reflects years of focused strategy, disciplined execution, and a relentless commitment to doing things the right way.'
A hall of server racks, illuminated by blue LED lights and humming with energy.
Following the news, HC Wainwright maintained CleanSpark, Inc. (NASDAQ:CLSK) as its 'top pick' in the Bitcoin mining sector in 2025, citing expectations for more bullish estimate revisions, higher Bitcoin prices in the remainder of the year, and multiple expansion on its stock, especially with its price currently at a 35-percent discount compared with companies with the same market capitalization.
While we acknowledge the potential of CLSK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio
Axios
2 hours ago
- Axios
Senate ekes out late-night win on Trump's "big, beautiful bill"
Senate Republicans voted 51-49 late Saturday to move forward with President Trump's " big, beautiful bill" — clearing a significant hurdle and setting up a lengthy weekend to pass the legislation. Why it matters: After days of heated debate and complaints, Senate Majority Leader John Thune (R-S.D.) is barreling forward to get Trump's priorities on taxes, the debt ceiling, border security and military funding passed by July 4. All Republicans but Rand Paul (R-Ky.) and Thom Tillis (R-N.C.) ultimately voted yes, making the final tally 51-49. But GOP holdouts — notably Sens. Ron Johnson (Wisc.), Mike Lee (Utah), Rick Scott (Fla.) and Cynthia Lummis (Wyo.) — forced the vote to remain open for more than three hours while they negotiated with party leaders, including Vice President JD Vance. Johnson told reporters on Saturday that holdouts were promised a vote on an amendment that would reduce the federal matching share for some new Medicaid enrollees. Scott has been pushing the approach. What to watch: Democrats are forcing the entire 940-page bill to be read on the floor, a process that could take well over 10 hours. Hours of debate, followed by a series of unlimited amendment votes, known as a vote-a-rama, will happen before final passage can take place. Zoom in: Sen. Marsha Blackburn (R-Tenn.) plans to offer an amendment to strike a temporary pause on states passing AI regulations. It is likely to be adopted, given that other Republicans, including Sen. Josh Hawley (R-Mo.), also are unhappy with the measure. Lee, as the vote was ongoing, announced he would withdraw his plan to sell off public lands to private housing developers. Several other GOP senators, including Sens. Steve Daines (R-Mont.) and Mike Crapo (R-Idaho), opposed Lee's provision. Between the lines: Trump ramped up pressure on Republicans on Saturday morning, circulating a statement of administration policy urging the bill's passage. "President Trump is committed to keeping his promises, and failure to pass this bill would be the ultimate betrayal," the statement read. Senators have been receiving phone calls, lunching and golfing with the president this weekend. The big picture: The new text would delay implementation of a reduced Medicaid provider tax in expansion states. It includes a compromise with the House to raise the cap on the state and local tax deduction to $40,000 for five years before reverting to the current $10,000 cap. It would create a $25 billion rural hospital fund, bumped up from $15 billion, an attempt to assuage concerns from some Republicans that bill's Medicaid cuts would devastate rural health providers.
USA Today
2 hours ago
- USA Today
Trump, 3 GOP senators play golf ahead of push for megabill vote
As the Senate wrestled with whether to begin debate on President Donald Trump's megabill, a few key Republican allies spent part of the afternoon golfing with the president at his nearby club in Northern Virginia. Trump, CIA Director John Ratcliffe and GOP Sens. Eric Schmitt of Missouri, Rand Paul of Kentucky and Lindsey Graham of South Carolina played golf a few hours before the Senate voted to debate the so-called 'Big Beautiful Bill.' Live updates: It's go time for Senate on Trump's megabill. Do they have the votes? Graham posted a photo of himself and Trump on social media as gave the camera a thumbs up. Graham said in a post that he partnered with Trump and Paul to beat Schmitt and Ratcliffe. "Proud to announce no casualties," Graham wrote. "A lot of fun! Big Beautiful Bill on the way." Schmitt posted a similar photo of himself and the president, writing "Big week for President Trump and he crushed it on the golf course this morning as well." Looking forward to beginning the One Big Beautiful Bill the day with @POTUS and thanked him for his Go! White House press secretary Karoline Leavitt told reporters around 2 p.m. that the president was wrapping up lunch and would soon depart the course, located about 25 miles from the White House. Senate Republican leaders launched the debate June 28 that is expected to culminate with a vote June 29 or 30 on the 990-page bill. While Democrats are all expected to vote no on the massive legislative package, the open question going into the debate is whether enough Republicans will end up supporting the Senate's version, which would send it back to the House. Trump has asked Congress to send him the completed bill to sign by July 4. The megabill is stuffed with tax cuts, Medicaid reforms and border security funding, containing several signature campaign promises from Trump and the Republican party. Kathryn Palmer is a national trending news reporter for USA TODAY. You can reach her at kapalmer@ and on X @KathrynPlmr.
